Truist Financial Corp Sells 1,981 Shares of Solventum Corporation $SOLV

Truist Financial Corp decreased its stake in shares of Solventum Corporation (NYSE:SOLV) by 3.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 64,441 shares of the company’s stock after selling 1,981 shares during the period. Truist Financial Corp’s holdings in Solventum were worth $4,887,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of SOLV. Rossby Financial LCC bought a new stake in shares of Solventum during the 1st quarter valued at about $25,000. Strengthening Families & Communities LLC boosted its stake in shares of Solventum by 376.8% during the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after purchasing an additional 260 shares in the last quarter. Hara Capital LLC purchased a new position in Solventum during the 1st quarter valued at about $38,000. Smartleaf Asset Management LLC lifted its position in Solventum by 193.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after acquiring an additional 352 shares during the period. Finally, Costello Asset Management INC purchased a new position in Solventum during the 1st quarter valued at about $42,000.

Solventum Stock Performance

Shares of SOLV stock opened at $72.22 on Wednesday. The company has a 50 day moving average price of $72.78 and a 200-day moving average price of $72.16. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $85.92. The firm has a market capitalization of $12.52 billion, a PE ratio of 33.43, a P/E/G ratio of 3.00 and a beta of 0.50. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. During the same period in the previous year, the business posted $1.56 earnings per share. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, equities research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current year.

Wall Street Analyst Weigh In

SOLV has been the subject of a number of recent research reports. Wells Fargo & Company lifted their price target on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Wall Street Zen cut shares of Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Solventum in a research report on Saturday, September 27th. Finally, Jefferies Financial Group initiated coverage on shares of Solventum in a research report on Thursday, September 11th. They set a “hold” rating and a $80.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus target price of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.